| P50 | author | Shibo Jiang | Q88118974 |
| P2093 | author name string | Chen Wang | |
| | Yuanyuan Zhang | |
| | Xuebing Li | |
| | Hui Xing | |
| | Liying Ma | |
| | Huihui Chong | |
| | Yibo Ding | |
| | Shuihong Cheng | |
| P2860 | cites work | Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 |
| | Anti-PEG immunity: emergence, characteristics, and unaddressed questions | Q26825556 |
| | Current perspectives on HIV-1 antiretroviral drug resistance | Q26852626 |
| | Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1 | Q27683583 |
| | Atomic structure of the ectodomain from HIV-1 gp41 | Q27738021 |
| | HIV entry and its inhibition | Q28273919 |
| | PEGylation, successful approach to drug delivery | Q28278538 |
| | An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors | Q28477736 |
| | Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression | Q28542678 |
| | Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity | Q33559031 |
| | An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life | Q33559066 |
| | Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility | Q34149681 |
| | Resistance to enfuvirtide, the first HIV fusion inhibitor | Q34330766 |
| | Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes | Q35697595 |
| | The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes | Q35859896 |
| | Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains | Q36945152 |
| | Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice | Q36990220 |
| | Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency | Q37153758 |
| | Current peptide HIV type-1 fusion inhibitors | Q37606219 |
| | Systematic review of HIV drug resistance in Southeast Asia. | Q37639245 |
| | PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery | Q37926601 |
| | Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket | Q38076321 |
| | A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol | Q38607635 |
| | Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity | Q38741307 |
| | Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics | Q38962851 |
| | Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). | Q39079796 |
| | A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats | Q39177353 |
| | MODFIT: a pharmacokinetics computer program | Q39261296 |
| | Phylodynamics of major CRF01_AE epidemic clusters circulating in mainland of China | Q40109918 |
| | A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity | Q40267838 |
| | Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties | Q40653699 |
| | Development of potent and long-acting HIV-1 fusion inhibitors | Q40885132 |
| | Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity | Q42174829 |
| | Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy | Q42258031 |
| | Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor | Q46731651 |
| | Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation. | Q51757859 |
| | Emerging reverse transcriptase inhibitors for HIV-1 infection. | Q53686168 |
| | Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide | Q57039664 |
| | Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals | Q57200837 |
| | Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4 | Q61818479 |
| | A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life | Q64066846 |
| | Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors | Q75223659 |
| | Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis | Q80051723 |
| | Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC | Q83451566 |
| | Structural and functional characterization of HIV-1 cell fusion inhibitor T20 | Q90871008 |
| | Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries | Q93002868 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P577 | publication date | 2019-09-02 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action | |
| P478 | volume | 11 | |